로딩 중…
지수 로딩 중…
Vaxcell-Bio Therapeutics Co., Ltd.
323990· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,585-6.52%
2026-06-19
Price Chart
Vaxcell-Bio Therapeutics Co., Ltd.-52.34%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 106.63B KRW |
| Revenue | 6.87B KRW |
| Net Income | -5.57B KRW |
| Total Assets | 63.60B KRW |
| Net Assets | 57.22B KRW |
| Employees | 81 |
| Value | |
| P/B | 1.86x |
| P/S | 15.52x |
| FCF Yield | -15.63% |
| Profitability | |
| ROE | -9.74% |
| ROA | -8.76% |
| Op. Margin | -230.16% |
| Revenue Growth | -10.70% |
| Financial Health | |
| Debt Ratio | 11.15% |
| Total Debt | 0 KRW |
| FCF | -16.67B KRW |
| Cash | 10.37B KRW |
| Current Ratio | 6.15x |
| Performance | |
| 1Y Return | -52.34% |
| 1M Return | -22.55% |
| From 52W High | -60.20% |
| 1Y MDD | -58.32% |
| Trading | |
| Volume | 131,388 shares |
| Foreign Own. | 7.26% |
| Per Share | |
| EPS | -632 KRW |
| BPS | 2,469 KRW |
Company Info
Established in 2010 as a specialized company for developing anticancer immunotherapeutics, the company was listed on the KOSDAQ market in 2020. It has built diverse pipelines, including the innate immune system-based Vax-NK anticancer immunotherapy platform, the next-generation Vax-CAR series platform, small molecule compound targeted anticancer drugs, bispecific antibody new drugs, DDS-based drug development, and a pet healthcare business. The company continuously innovates to realize its vision of a better world through immunotherapies, focusing on key elements of the immune system. Vaxcell-Bio was established in 2010 and is headquartered in Jeollanam-do, Hwasun-gun.